Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14 | $49 | $43 | $44 |
| - Cash | $4 | $7 | $9 | $13 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $10 | $41 | $34 | $31 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $0 | -$15 | -$12 | -$13 |
| % Margin | – | – | – | – |
| Net Income | -$14 | -$15 | -$12 | -$13 |
| % Margin | – | – | – | – |
| EPS Diluted | -17.59 | -23.01 | -22.36 | -24.96 |
| % Growth | 23.6% | -2.9% | 10.4% | – |
| Operating Cash Flow | -$10 | -$10 | -$8 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$10 | -$10 | -$8 | -$5 |